Qiagen NV's $1.42 billion acquisition of Digene Corp. in mid-2007 surprised the industry. [See Deal] With a business model geared towards high-volume, platform-oriented economies of scale rather than high-value, focused content like Digene's molecular diagnostic HPV test, the Dutch sample prep and assay specialist was not seen as a major player in the evolving molecular space. Now, Qiagen has bought up Qiagen Manchester Ltd., a privately held UK-based provider of molecular tests including one for the mutant oncogene KRAS, the companion diagnostic featured as of July 2009 on the labels of the EGF receptor targeting drugs panitumumab (Vectibix) and cetuximab (Erbitux) (cetuximab) for metastatic colon cancer, from Amgen Inc. and Bristol-Myers Squibb Co. and partner ImClone Systems Inc. (part of Eli Lilly & Co.), respectively. [See Deal][See Deal][See Deal]
Qiagen is paying $95 million in cash for DxS, with the promise of an additional $35 million conditioned on achievement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?